The vaccine, known as Ad5-nCoV, was jointly-developed by the Beijing Institute of Biotechnology — part of the Chinese government’s Academy of Military Medical Sciences — and vaccine company CanSino Biologics.
US observers, however, have cast doubt on the claims, noting that the PLA is the among the world’s largest standing armies, making it statistically unlikely that its personnel have not been exposed to the virus.
Neither the Chinese government nor CanSino have said how broadly the vaccine will be distributed, which units were be selected or whether it will be mandatory or voluntary for personnel.
CNN has reached out for CanSino for comment on the announcement.
According to a CanSino statement, clinical trials of the new vaccine have shown a “good safety profile” with initial results indicating that Ad5-nCoV had potential to prevent diseases caused by SARS-CoV-2, the coronavirus strain that causes Covid-19.
China is just one of several countries rushing to produce a vaccine for the novel coronavirus, which has now infected more than 10.3 million people worldwide and killed at least 505,000.
According to the statement from CanSino, the first and second phases of their Ad5-nCoV vaccine trials have already been completed.
News by Editor